MWM
LGND icon

Meridian Wealth Management’s Ligand Pharmaceuticals LGND Stock Holding History

Meridian Wealth Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$253K Buy
+801
New +$189K 0.01% 727
2020
Q3 		– Sell
-9,826
Closed -$685K – 272
2020
Q2 		$685K Buy
+9,826
New +$623K 0.23% 96

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meridian Wealth Management's LGND Position: Q2 2026 in Review

Meridian Wealth Management opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 801 shares worth $253K. The stake represents 0.01% of the portfolio and ranks #727 among its holdings. This is a return to the name: Meridian Wealth Management previously reported a position in LGND as recently as Q2 2020.

Meridian Wealth Management first reported a position in LGND in Q2 2020 and has held it in 2 quarters since. The position peaked at $685K in Q2 2020. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Meridian Wealth Management held 801 shares of Ligand Pharmaceuticals worth $253K as of Q2 2026.
  • Ligand Pharmaceuticals was a new Meridian Wealth Management position in Q2 2026.
  • Ligand Pharmaceuticals made up 0.01% of Meridian Wealth Management's portfolio in Q2 2026, its #727 holding.
  • Meridian Wealth Management first reported a position in Ligand Pharmaceuticals in Q2 2020 and has held it in 2 quarters since.
  • Meridian Wealth Management's Ligand Pharmaceuticals position peaked at $685K in Q2 2020.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Meridian Wealth Management's 13F filing for Q2 2026, filed 5 Aug 2026.